Comera Life Sciences Holdings (Comera Life Sciences Holdings) Long-Term Capital Lease Obligation : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Comera Life Sciences Holdings Long-Term Capital Lease Obligation?

Comera Life Sciences Holdings's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil.

Comera Life Sciences Holdings's quarterly Long-Term Capital Lease Obligation declined from Mar. 2023 ($0.05 Mil) to Jun. 2023 ($0.00 Mil) but then stayed the same from Jun. 2023 ($0.00 Mil) to Sep. 2023 ($0.00 Mil).

Comera Life Sciences Holdings's annual Long-Term Capital Lease Obligation increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($0.20 Mil) but then declined from Dec. 2021 ($0.20 Mil) to Dec. 2022 ($0.12 Mil).

Comera Life Sciences Holdings Long-Term Capital Lease Obligation Historical Data

The historical data trend for Comera Life Sciences Holdings's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Comera Life Sciences Holdings Long-Term Capital Lease Obligation Chart

Comera Life Sciences Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Long-Term Capital Lease Obligation

0.20

0.12

Comera Life Sciences Holdings Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial						0.17	0.12	0.05	-	-

Comera Life Sciences Holdings (OTCPK:CMRA) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Comera Life Sciences Holdings Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Comera Life Sciences Holdings's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Comera Life Sciences Holdings (Comera Life Sciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Comera Life Sciences Holdings Inc (OTCPK:CMRA) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Gill Street, Suite 4650, Woburn, MA, USA, 01801

Website

https://www.comeralifesciences.com

Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.

Executives

Michael Gerard Campbell	officer: Chief Financial Officer	C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Charles Cherington	10 percent owner	ONE BOW STREET, CAMBRIDGE MA 02138
David Soane	10 percent owner	C/O SOANE LABS, LLC, 380 NE 72ND TERRACE, MIAMI FL 33138
Robert Patrick Mahoney	officer: Chief Scientific Officer	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Barbara K Finck	director	C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118
Kirsten Flowers	director	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
James Sherblom	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Stuart A Randle	director	585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Sullivan Edward Aloysius Jr.	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Sirshendu Roopom Banerjee	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Janice Mccourt	officer: Chief Business Officer	C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Jeffrey S. Hackman	director, officer: See Remarks	12 GILL STREET, SUITE 4650, WOBURN MA 01801
John D. Yee	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Neal Muni	officer: See Remarks	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Phoenix Venture Partners Lp	10 percent owner	36 DOCKSIDE CIRCLE, REDWOOD SHORES CA 94065